Kentner Rainer, Safar Peter, Behringer Wilhelm, Wu Xianren, Henchir Jeremy, Ma Li, Hsia Carleton J C, Tisherman Samuel A
Safar Center for Resuscitation Research, University of Pittsburgh, 3434 Fifth Avenue, Pittsburgh, PA 15260, USA.
Resuscitation. 2007 Feb;72(2):295-305. doi: 10.1016/j.resuscitation.2006.05.025. Epub 2006 Nov 16.
In a previous study, titration of a hypertonic saline (HTS) solution during severe uncontrolled hemorrhagic shock (UHS) failed to reduce mortality. In a separate study, a novel antioxidant, polynitroxylated albumin (PNA) plus tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), infused during shock increased long-term survival. We hypothesized that combining potent antioxidants with a hypertonic solution during UHS would preserve the logistical advantage of small volume resuscitation and improve survival.
An UHS outcome model in rats was used. UHS phase I (90 min) included blood withdrawal of 30 ml/kg over 15 min, followed by tail amputation for uncontrolled bleeding. At 20 min, rats were randomized to four groups (n=10 each) for hypotensive resuscitation from 20 to 90 min (mean arterial pressure [MAP] > or = 40 mmHg): HTS/starch group received 7.2% NaCl/10% hydroxyethyl starch; HTS/albumin group received 7.5% NaCl/20% albumin; HTS/PNA group received 7.5% NaCl/20% PNA; HTS/albumin+tempol group received 7.5% NaCl/20% albumin plus tempol. Resuscitation phase II (180 min) included hemostasis, return of shed blood and administration of fluids to restore MAP > or = 80 mmHg. Observation phase III was to 72 h.
The total amount of fluid required to maintain hypotensive MAP during HS was low and did not differ between groups (range: 3.4+/-1.9 to 5.3+/-2.5 ml/kg). The rate of fluid administration required was higher in the HTS/albumin+tempol group compared to all other groups (p=0.006). Additional uncontrolled blood loss was highest in the HTS/PNA group (16.2+/-5.7 ml/kg [p=0.01] versus 10.4+/-7.9 ml/kg in the HTS/starch group, 7.7+/-5.2 ml/kg in the HTS/albumin group and 8.2+/-7.1 ml/kg in the HTS/albumin+tempol group). MAP after start of resuscitation in phase I was lower in the HTS/albumin+tempol group than the HTS/albumin or HTS/PNA groups (p<0.01). This group was also less tachycardic. Long-term survival was low in all groups (2 of 10 after HTS/starch and 1 of 10 after HTS/albumin, 3 of 10 after HTS/PNA, 1 of 10 after HTS/albumin+tempol). Median survival time was shortest in the HTS/albumin+tempol group (72 min [CI 34-190]) compared to all other groups (p=0.01).
Despite its benefits in other model systems, free tempol is potentially hazardous when combined with hypertonic fluids. PNA abrogates these deleterious effects on acute mortality but may lead to increased blood loss in the setting of UHS.
在之前的一项研究中,在严重失控性出血性休克(UHS)期间滴定高渗盐水(HTS)溶液未能降低死亡率。在另一项研究中,一种新型抗氧化剂,多硝基化白蛋白(PNA)加Tempol(4-羟基-2,2,6,6-四甲基哌啶-N-氧基),在休克期间输注可提高长期生存率。我们假设在UHS期间将强效抗氧化剂与高渗溶液联合使用将保留小容量复苏的后勤优势并提高生存率。
使用大鼠UHS结局模型。UHS第一阶段(90分钟)包括在15分钟内抽取30 ml/kg血液,然后进行断尾以造成失控性出血。在20分钟时,将大鼠随机分为四组(每组n = 10),在20至90分钟内进行低血压复苏(平均动脉压[MAP]≥40 mmHg):HTS/淀粉组接受7.2% NaCl/10%羟乙基淀粉;HTS/白蛋白组接受7.5% NaCl/20%白蛋白;HTS/PNA组接受7.5% NaCl/20% PNA;HTS/白蛋白+Tempol组接受7.5% NaCl/20%白蛋白加Tempol。复苏第二阶段(180分钟)包括止血、回输失血并给予液体以恢复MAP≥80 mmHg。观察第三阶段至72小时。
在HS期间维持低血压MAP所需的液体总量较低,且各组之间无差异(范围:3.4±1.9至5.3±2.5 ml/kg)。与所有其他组相比,HTS/白蛋白+Tempol组所需的液体输注速率更高(p = 0.006)。HTS/PNA组额外的失控性失血量最高(16.2±5.7 ml/kg [p = 0.01],而HTS/淀粉组为10.4±7.9 ml/kg,HTS/白蛋白组为7.7±5.2 ml/kg,HTS/白蛋白+Tempol组为8.2±7.1 ml/kg)。在第一阶段复苏开始后,HTS/白蛋白+Tempol组的MAP低于HTS/白蛋白组或HTS/PNA组(p<0.01)。该组的心动过速也较轻。所有组的长期生存率都很低(HTS/淀粉组10只中有2只,HTS/白蛋白组10只中有1只,HTS/PNA组10只中有3只,HTS/白蛋白+Tempol组10只中有1只)。与所有其他组相比,HTS/白蛋白+Tempol组的中位生存时间最短(72分钟[CI 34 - 190])(p = 0.01)。
尽管游离Tempol在其他模型系统中有益处,但与高渗液体联合使用时可能具有潜在危险性。PNA可消除这些对急性死亡率的有害影响,但在UHS情况下可能导致失血量增加。